Abstract:Targeted therapies have replaced conventional chemotherapy as first-line treatment for patients with non-small cell lung cancers harboring epidermal growth factor receptor (EGFR) alterations. Although tyrosine-kinase inhibitors (TKI) targeting these proteins lead to responses in ∼70% of cases, tumors almost inevitably become resistant. Acquired resistance is commonly caused by secondary mutations in the target oncogene, activation of bypass signaling pathways, histologic transformation of the tumor, or unknown mechanisms (∼20-40%). Epigenetic mechanisms are responsible for regulating genes involved in cell lineage specificity, and they are known to modulate tumorigenesis. In recent years, several epigenetic modifiers have also been implicated in processes related to drug resistance. We hypothesized that dysfunction of epigenetic processes plays a role in mediating resistance to TKIs. To examine this possibility, we generated three isogenic osimertinib-sensitive/resistant cell line pairs and mined whole-exome and RNA sequencing (RNA-seq) data. Distinct alterations and phenotypes were identified in the different models, highlighting the importance of the baseline biologic context for the type of osimertinib resistance mechanism that emerges. Using RNA-seq data, we searched for epigenetic regulators that might be mediating the differentially expressed genes in the resistant cells. This analysis revealed that the chromatin remodeling protein SMARCA4/BRG1 is required for maintenance of the resistant phenotype in one of the models as knockdown of BRG1 sensitized cells to osimertinib. Further analysis revealed that SMARCA4 is stabilized in TKI-resistant cells, thus leading to TKI resistance. Finally, immunohistochemistry (IHC) examination of a collection of TKI-resistant patient-derived xenografts (PDXs) revealed higher levels of SMARCA4 expression in TKI-resistant tumors without on-target EGFR-dependent resistant mechanisms. To further elucidate the role of SMARCA4, we are currently performing ATAC-seq experiments that will offer insights into chromatin accessibility mediated by the protein in the resistant cells. In addition, we are assessing the protein levels of SMARCA4 in clinical specimens obtained before treatment and at the time of resistance by IHC. As new and better targeted therapies are developed, complex resistance mechanisms that involve epigenetic changes in tumors are likely to be increasingly observed. Our studies offer insights into the mechanisms that underlie such resistance that could lead to new therapeutic possibilities for these tumors.

MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC

L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance

L3MBTL1, a polycomb protein, promotes Osimertinib acquired resistance through epigenetic regulation of DNA damage response in lung adenocarcinoma

Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition

P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer

Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer

Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer

Potential Resistance Mechanisms Using Next Generation Sequencing from Chinese EGFR T790M+ Non-Small Cell Lung Cancer Patients with Primary Resistance to Osimertinib: A Multicenter Study

Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages

Blockade of STAT3/IL-4 Overcomes EGFR T790M-cis-L792F-induced Resistance to Osimertinib Via Suppressing M2 Macrophages Polarization

ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC

B30 the Role of SMARCA4 As an EGFR-Independent Mechanism of Resistance to Osimertinib

Disclosing Potential Therapeutic Targets Associated With Osimertinib Resistance in the Non-small Cell Lung Cancer Cell Line H1975